| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polyethylene Glycols | 99 | 2019 | 360 | 9.200 |
Why?
|
| Biocompatible Materials | 63 | 2024 | 198 | 6.670 |
Why?
|
| Polymers | 50 | 2023 | 196 | 5.300 |
Why?
|
| Hydrogels | 40 | 2019 | 87 | 5.080 |
Why?
|
| Fibrin | 46 | 2022 | 86 | 4.880 |
Why?
|
| Extracellular Matrix | 34 | 2019 | 245 | 4.080 |
Why?
|
| Collagen | 24 | 2021 | 294 | 3.750 |
Why?
|
| Immunotherapy | 16 | 2024 | 699 | 3.700 |
Why?
|
| Nanoparticles | 30 | 2018 | 165 | 3.690 |
Why?
|
| Tissue Engineering | 31 | 2024 | 191 | 3.390 |
Why?
|
| Drug Carriers | 19 | 2019 | 82 | 3.280 |
Why?
|
| Immune Tolerance | 10 | 2023 | 341 | 3.250 |
Why?
|
| Dendritic Cells | 26 | 2024 | 451 | 3.240 |
Why?
|
| Interleukin-12 | 5 | 2024 | 111 | 3.210 |
Why?
|
| Animals | 207 | 2024 | 27536 | 3.010 |
Why?
|
| Sulfides | 22 | 2015 | 68 | 2.870 |
Why?
|
| Drug Delivery Systems | 25 | 2021 | 178 | 2.810 |
Why?
|
| Arthritis, Experimental | 4 | 2024 | 26 | 2.730 |
Why?
|
| Mice | 102 | 2024 | 11858 | 2.680 |
Why?
|
| Micelles | 20 | 2024 | 48 | 2.670 |
Why?
|
| Peptides | 26 | 2023 | 649 | 2.610 |
Why?
|
| Protein Engineering | 20 | 2021 | 145 | 2.560 |
Why?
|
| Melanoma, Experimental | 11 | 2019 | 111 | 2.550 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 4 | 2024 | 61 | 2.520 |
Why?
|
| Antigens | 11 | 2023 | 229 | 2.500 |
Why?
|
| Vaccines | 13 | 2024 | 84 | 2.450 |
Why?
|
| Cell Adhesion | 44 | 2017 | 426 | 2.450 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 10 | 2019 | 182 | 2.420 |
Why?
|
| CD8-Positive T-Lymphocytes | 19 | 2021 | 600 | 2.290 |
Why?
|
| Arthritis, Rheumatoid | 4 | 2024 | 171 | 2.280 |
Why?
|
| Serum Albumin | 5 | 2021 | 128 | 2.260 |
Why?
|
| Fibronectins | 12 | 2019 | 101 | 2.250 |
Why?
|
| Melanoma | 6 | 2023 | 471 | 2.170 |
Why?
|
| Adjuvants, Immunologic | 11 | 2024 | 169 | 2.160 |
Why?
|
| Neovascularization, Physiologic | 17 | 2022 | 143 | 2.150 |
Why?
|
| Prodrugs | 5 | 2024 | 52 | 2.090 |
Why?
|
| Butyrates | 4 | 2024 | 46 | 2.070 |
Why?
|
| Mice, Inbred C57BL | 44 | 2024 | 3253 | 2.010 |
Why?
|
| Cell Culture Techniques | 18 | 2017 | 194 | 1.830 |
Why?
|
| Cancer Vaccines | 6 | 2021 | 159 | 1.790 |
Why?
|
| Recombinant Fusion Proteins | 8 | 2021 | 563 | 1.770 |
Why?
|
| Vascular Endothelial Growth Factor A | 19 | 2022 | 405 | 1.710 |
Why?
|
| Cells, Cultured | 61 | 2021 | 2887 | 1.660 |
Why?
|
| Lymph Nodes | 11 | 2021 | 550 | 1.640 |
Why?
|
| Oligopeptides | 16 | 2007 | 188 | 1.630 |
Why?
|
| Immunity, Humoral | 4 | 2021 | 66 | 1.510 |
Why?
|
| Bioengineering | 4 | 2024 | 14 | 1.490 |
Why?
|
| Antibodies | 8 | 2023 | 353 | 1.470 |
Why?
|
| Fibroblasts | 26 | 2014 | 759 | 1.450 |
Why?
|
| Pulmonary Fibrosis | 2 | 2024 | 138 | 1.420 |
Why?
|
| Recombinant Proteins | 16 | 2021 | 1008 | 1.390 |
Why?
|
| Wound Healing | 16 | 2023 | 362 | 1.370 |
Why?
|
| T-Lymphocytes | 8 | 2021 | 1221 | 1.360 |
Why?
|
| Delayed-Action Preparations | 14 | 2023 | 110 | 1.360 |
Why?
|
| Antigen Presentation | 7 | 2021 | 215 | 1.320 |
Why?
|
| Heparin | 11 | 2018 | 185 | 1.280 |
Why?
|
| Fibrinolysin | 11 | 2017 | 26 | 1.250 |
Why?
|
| Humans | 170 | 2024 | 90014 | 1.200 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 20 | 2014 | 31 | 1.190 |
Why?
|
| Cell Movement | 19 | 2017 | 787 | 1.180 |
Why?
|
| Erythrocytes | 6 | 2021 | 254 | 1.160 |
Why?
|
| Endothelium, Vascular | 15 | 2006 | 435 | 1.160 |
Why?
|
| Cross-Priming | 4 | 2021 | 49 | 1.160 |
Why?
|
| Bone Morphogenetic Proteins | 8 | 2021 | 127 | 1.160 |
Why?
|
| Ovalbumin | 13 | 2021 | 109 | 1.150 |
Why?
|
| Inflammation | 6 | 2022 | 981 | 1.150 |
Why?
|
| Acetylgalactosamine | 3 | 2023 | 8 | 1.130 |
Why?
|
| Cross-Linking Reagents | 14 | 2017 | 88 | 1.130 |
Why?
|
| Tissue Scaffolds | 9 | 2017 | 116 | 1.130 |
Why?
|
| Coated Materials, Biocompatible | 12 | 2014 | 30 | 1.100 |
Why?
|
| Regenerative Medicine | 4 | 2015 | 25 | 1.090 |
Why?
|
| Macrophages | 8 | 2021 | 582 | 1.050 |
Why?
|
| Bone Regeneration | 10 | 2022 | 62 | 1.050 |
Why?
|
| Membranes, Artificial | 10 | 2014 | 38 | 1.040 |
Why?
|
| Cell Proliferation | 31 | 2019 | 1670 | 1.040 |
Why?
|
| Neurites | 9 | 2019 | 36 | 1.030 |
Why?
|
| Immunity, Cellular | 4 | 2021 | 178 | 1.020 |
Why?
|
| Rats | 54 | 2023 | 4048 | 1.010 |
Why?
|
| Microfluidics | 5 | 2019 | 54 | 1.010 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2016 | 91 | 0.970 |
Why?
|
| Cytokines | 7 | 2022 | 811 | 0.950 |
Why?
|
| Doxorubicin | 6 | 2019 | 293 | 0.940 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2024 | 111 | 0.940 |
Why?
|
| Biological Availability | 3 | 2024 | 91 | 0.940 |
Why?
|
| Polylysine | 8 | 2006 | 34 | 0.940 |
Why?
|
| Drug Design | 5 | 2013 | 126 | 0.930 |
Why?
|
| Transforming Growth Factor beta | 9 | 2021 | 326 | 0.930 |
Why?
|
| Gene Transfer Techniques | 5 | 2014 | 153 | 0.920 |
Why?
|
| Laminin | 5 | 2018 | 89 | 0.920 |
Why?
|
| Materials Testing | 27 | 2016 | 93 | 0.910 |
Why?
|
| Myofibroblasts | 1 | 2024 | 48 | 0.900 |
Why?
|
| Fibrosis | 2 | 2024 | 236 | 0.900 |
Why?
|
| Milk Hypersensitivity | 1 | 2023 | 10 | 0.900 |
Why?
|
| Gels | 19 | 2014 | 49 | 0.890 |
Why?
|
| Placenta Growth Factor | 5 | 2019 | 71 | 0.890 |
Why?
|
| Sulfhydryl Compounds | 7 | 2010 | 71 | 0.890 |
Why?
|
| Serine | 1 | 2024 | 105 | 0.890 |
Why?
|
| Anaphylaxis | 1 | 2023 | 33 | 0.880 |
Why?
|
| Antibody Formation | 2 | 2023 | 171 | 0.880 |
Why?
|
| Neoplasms | 10 | 2021 | 3067 | 0.870 |
Why?
|
| Cysteine | 1 | 2024 | 137 | 0.860 |
Why?
|
| Integrins | 12 | 2015 | 78 | 0.860 |
Why?
|
| Disease Models, Animal | 16 | 2024 | 2395 | 0.860 |
Why?
|
| Islets of Langerhans | 8 | 2017 | 549 | 0.850 |
Why?
|
| Monocytes | 4 | 2017 | 221 | 0.840 |
Why?
|
| Peptide Fragments | 12 | 2019 | 463 | 0.820 |
Why?
|
| Food Hypersensitivity | 1 | 2023 | 72 | 0.820 |
Why?
|
| Protein Binding | 18 | 2022 | 1492 | 0.820 |
Why?
|
| Nanostructures | 6 | 2017 | 79 | 0.800 |
Why?
|
| Nanotechnology | 7 | 2013 | 68 | 0.790 |
Why?
|
| Oligodeoxyribonucleotides | 4 | 2016 | 125 | 0.780 |
Why?
|
| Regeneration | 13 | 2022 | 151 | 0.780 |
Why?
|
| Cell Differentiation | 16 | 2024 | 1533 | 0.780 |
Why?
|
| Amino Acid Sequence | 28 | 2019 | 2064 | 0.760 |
Why?
|
| Eryptosis | 1 | 2021 | 1 | 0.750 |
Why?
|
| Foot Joints | 1 | 2021 | 4 | 0.750 |
Why?
|
| Biological Products | 1 | 2023 | 161 | 0.740 |
Why?
|
| Antineoplastic Agents | 7 | 2019 | 2331 | 0.730 |
Why?
|
| Cell Line, Tumor | 12 | 2024 | 2588 | 0.730 |
Why?
|
| Immunoconjugates | 2 | 2019 | 114 | 0.720 |
Why?
|
| Mice, Inbred BALB C | 11 | 2020 | 1091 | 0.720 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2019 | 346 | 0.720 |
Why?
|
| Chick Embryo | 16 | 2017 | 230 | 0.710 |
Why?
|
| Porphyrins | 3 | 2009 | 40 | 0.710 |
Why?
|
| Matrix Metalloproteinase 2 | 5 | 2010 | 48 | 0.710 |
Why?
|
| Surface Properties | 25 | 2012 | 131 | 0.710 |
Why?
|
| Spinal Fusion | 1 | 2021 | 86 | 0.710 |
Why?
|
| Integrin alpha Chains | 2 | 2019 | 16 | 0.700 |
Why?
|
| Interleukin-10 | 1 | 2021 | 155 | 0.700 |
Why?
|
| Interleukin-4 | 1 | 2020 | 129 | 0.690 |
Why?
|
| Hepatocytes | 1 | 2021 | 122 | 0.690 |
Why?
|
| Chemokine CCL4 | 1 | 2019 | 9 | 0.690 |
Why?
|
| Endothelial Cells | 14 | 2014 | 464 | 0.670 |
Why?
|
| Immunosuppressive Agents | 4 | 2020 | 979 | 0.660 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2019 | 700 | 0.660 |
Why?
|
| B-Lymphocytes | 4 | 2023 | 740 | 0.650 |
Why?
|
| Glycoconjugates | 1 | 2019 | 10 | 0.640 |
Why?
|
| Antigens, Protozoan | 1 | 2019 | 21 | 0.640 |
Why?
|
| Tissue Adhesives | 5 | 2023 | 23 | 0.640 |
Why?
|
| Biomimetic Materials | 8 | 2013 | 24 | 0.640 |
Why?
|
| Tumor Microenvironment | 6 | 2024 | 476 | 0.640 |
Why?
|
| Glycosylation | 4 | 2023 | 128 | 0.640 |
Why?
|
| Antibodies, Neoplasm | 1 | 2019 | 84 | 0.640 |
Why?
|
| Tissue Adhesions | 9 | 2007 | 50 | 0.630 |
Why?
|
| Alginates | 5 | 2014 | 16 | 0.630 |
Why?
|
| Female | 53 | 2024 | 46617 | 0.620 |
Why?
|
| Antibody Affinity | 1 | 2018 | 38 | 0.620 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 5 | 2006 | 6 | 0.620 |
Why?
|
| Antigens, CD | 2 | 2019 | 466 | 0.620 |
Why?
|
| CD40 Antigens | 1 | 2018 | 44 | 0.620 |
Why?
|
| Imidazoles | 3 | 2017 | 140 | 0.610 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2016 | 319 | 0.600 |
Why?
|
| Polypropylenes | 8 | 2011 | 23 | 0.600 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 744 | 0.590 |
Why?
|
| Immunologic Memory | 3 | 2015 | 164 | 0.590 |
Why?
|
| Acrylates | 6 | 2005 | 18 | 0.590 |
Why?
|
| Urethra | 4 | 2024 | 116 | 0.590 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 799 | 0.580 |
Why?
|
| Nerve Regeneration | 4 | 2003 | 36 | 0.580 |
Why?
|
| Autoimmunity | 4 | 2023 | 169 | 0.570 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2017 | 28 | 0.570 |
Why?
|
| Bone Morphogenetic Protein 2 | 10 | 2021 | 48 | 0.560 |
Why?
|
| Disulfides | 6 | 2024 | 65 | 0.560 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 7 | 2015 | 95 | 0.560 |
Why?
|
| Rats, Sprague-Dawley | 24 | 2017 | 1237 | 0.560 |
Why?
|
| BCG Vaccine | 1 | 2017 | 36 | 0.550 |
Why?
|
| Water | 7 | 2012 | 286 | 0.550 |
Why?
|
| Urinary Bladder | 8 | 2016 | 248 | 0.550 |
Why?
|
| Cell Separation | 5 | 2017 | 199 | 0.540 |
Why?
|
| Adsorption | 14 | 2009 | 53 | 0.540 |
Why?
|
| Quinolines | 1 | 2017 | 86 | 0.540 |
Why?
|
| Mouse Embryonic Stem Cells | 1 | 2016 | 12 | 0.540 |
Why?
|
| Embryonic Stem Cells | 6 | 2013 | 81 | 0.540 |
Why?
|
| Photochemistry | 8 | 2010 | 38 | 0.530 |
Why?
|
| Th1 Cells | 3 | 2016 | 166 | 0.530 |
Why?
|
| Hepatitis B Vaccines | 1 | 2016 | 16 | 0.530 |
Why?
|
| Injections, Intravenous | 4 | 2021 | 238 | 0.530 |
Why?
|
| Ischemia | 3 | 2014 | 253 | 0.530 |
Why?
|
| Stem Cells | 6 | 2014 | 376 | 0.520 |
Why?
|
| Lung | 5 | 2019 | 1292 | 0.520 |
Why?
|
| Protein Domains | 4 | 2020 | 136 | 0.520 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2015 | 9 | 0.520 |
Why?
|
| Antibodies, Monoclonal | 4 | 2018 | 1396 | 0.520 |
Why?
|
| Molecular Sequence Data | 22 | 2014 | 3024 | 0.510 |
Why?
|
| Peripheral Tolerance | 1 | 2015 | 2 | 0.510 |
Why?
|
| Pharmaceutical Preparations | 4 | 2023 | 92 | 0.510 |
Why?
|
| von Willebrand Factor | 3 | 2019 | 37 | 0.500 |
Why?
|
| Integrin alphaVbeta3 | 3 | 2013 | 17 | 0.500 |
Why?
|
| Particle Size | 13 | 2017 | 126 | 0.490 |
Why?
|
| Thrombosis | 8 | 2005 | 302 | 0.490 |
Why?
|
| Biomedical Engineering | 5 | 2012 | 20 | 0.480 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 572 | 0.480 |
Why?
|
| Matrix Metalloproteinase 1 | 3 | 2014 | 17 | 0.480 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 146 | 0.460 |
Why?
|
| Lymphoma | 2 | 2015 | 266 | 0.460 |
Why?
|
| Prostheses and Implants | 11 | 2010 | 125 | 0.460 |
Why?
|
| Cell Communication | 5 | 2021 | 200 | 0.460 |
Why?
|
| Surface-Active Agents | 6 | 2014 | 61 | 0.450 |
Why?
|
| Angiogenesis Inducing Agents | 4 | 2013 | 30 | 0.450 |
Why?
|
| Transglutaminases | 8 | 2009 | 40 | 0.450 |
Why?
|
| Esters | 2 | 2023 | 30 | 0.450 |
Why?
|
| Hexuronic Acids | 4 | 2014 | 10 | 0.440 |
Why?
|
| Glucuronic Acid | 4 | 2014 | 11 | 0.440 |
Why?
|
| Cell Physiological Phenomena | 1 | 2013 | 24 | 0.440 |
Why?
|
| Proteins | 6 | 2024 | 787 | 0.440 |
Why?
|
| Solubility | 8 | 2021 | 185 | 0.440 |
Why?
|
| Dogs | 7 | 2024 | 706 | 0.430 |
Why?
|
| Immunity | 4 | 2019 | 141 | 0.430 |
Why?
|
| Protein Structure, Tertiary | 12 | 2015 | 740 | 0.420 |
Why?
|
| Fibrinogen | 8 | 2013 | 53 | 0.420 |
Why?
|
| Extracellular Matrix Proteins | 8 | 2017 | 127 | 0.410 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 312 | 0.410 |
Why?
|
| Antigen-Presenting Cells | 4 | 2021 | 142 | 0.410 |
Why?
|
| Silicon | 2 | 2009 | 18 | 0.400 |
Why?
|
| Lymphatic Vessels | 3 | 2013 | 68 | 0.400 |
Why?
|
| Protein Array Analysis | 2 | 2009 | 52 | 0.400 |
Why?
|
| Mice, Transgenic | 6 | 2021 | 1579 | 0.400 |
Why?
|
| Kidney | 3 | 2024 | 1148 | 0.390 |
Why?
|
| Lymphocyte Activation | 4 | 2024 | 754 | 0.390 |
Why?
|
| CD4-Positive T-Lymphocytes | 9 | 2019 | 450 | 0.390 |
Why?
|
| Islets of Langerhans Transplantation | 5 | 2017 | 242 | 0.390 |
Why?
|
| Polytetrafluoroethylene | 5 | 2007 | 74 | 0.390 |
Why?
|
| Membrane Glycoproteins | 3 | 2016 | 432 | 0.380 |
Why?
|
| Time Factors | 18 | 2024 | 5361 | 0.380 |
Why?
|
| Uterine Diseases | 3 | 1996 | 19 | 0.370 |
Why?
|
| Genetic Therapy | 4 | 2014 | 372 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-sis | 7 | 2015 | 29 | 0.370 |
Why?
|
| Drug Discovery | 1 | 2012 | 107 | 0.360 |
Why?
|
| Binding Sites | 9 | 2018 | 1122 | 0.360 |
Why?
|
| Fracture Healing | 4 | 2005 | 37 | 0.360 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2019 | 135 | 0.360 |
Why?
|
| Biopolymers | 3 | 2010 | 26 | 0.360 |
Why?
|
| Chemical Engineering | 1 | 2010 | 2 | 0.360 |
Why?
|
| Genetic Vectors | 4 | 2006 | 446 | 0.360 |
Why?
|
| Kinetics | 10 | 2015 | 1534 | 0.360 |
Why?
|
| Polyethylene Terephthalates | 6 | 1992 | 18 | 0.360 |
Why?
|
| Immobilized Proteins | 2 | 2013 | 14 | 0.360 |
Why?
|
| RNA, Small Interfering | 3 | 2013 | 557 | 0.360 |
Why?
|
| Ganglia, Spinal | 7 | 2005 | 75 | 0.360 |
Why?
|
| Hyaluronic Acid | 5 | 2012 | 51 | 0.350 |
Why?
|
| Microscopy, Atomic Force | 6 | 2011 | 53 | 0.350 |
Why?
|
| Magnetic Resonance Spectroscopy | 8 | 2010 | 316 | 0.350 |
Why?
|
| Osteogenesis | 4 | 2022 | 258 | 0.350 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 1983 | 0.350 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 4 | 2013 | 79 | 0.350 |
Why?
|
| Postoperative Complications | 7 | 2007 | 2316 | 0.340 |
Why?
|
| Myocytes, Smooth Muscle | 9 | 2019 | 140 | 0.340 |
Why?
|
| Biosensing Techniques | 3 | 2003 | 73 | 0.340 |
Why?
|
| Vaccination | 4 | 2019 | 279 | 0.340 |
Why?
|
| Catalysis | 5 | 2009 | 205 | 0.340 |
Why?
|
| Nanocapsules | 3 | 2017 | 11 | 0.340 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 1181 | 0.340 |
Why?
|
| Epitopes | 3 | 2022 | 254 | 0.330 |
Why?
|
| Phase Transition | 3 | 2005 | 18 | 0.330 |
Why?
|
| Nanomedicine | 1 | 2009 | 14 | 0.330 |
Why?
|
| Colloids | 3 | 2010 | 26 | 0.330 |
Why?
|
| Cellular Microenvironment | 3 | 2014 | 29 | 0.320 |
Why?
|
| Matrix Metalloproteinases | 4 | 2010 | 29 | 0.320 |
Why?
|
| Mice, Nude | 5 | 2019 | 816 | 0.320 |
Why?
|
| DNA | 5 | 2011 | 1311 | 0.320 |
Why?
|
| Cell Adhesion Molecules | 5 | 2005 | 166 | 0.320 |
Why?
|
| Microscopy, Electron, Scanning | 11 | 2019 | 141 | 0.320 |
Why?
|
| Transfection | 4 | 2011 | 909 | 0.320 |
Why?
|
| Spleen | 7 | 2020 | 433 | 0.320 |
Why?
|
| Cell Survival | 14 | 2018 | 983 | 0.310 |
Why?
|
| Mice, SCID | 4 | 2019 | 259 | 0.310 |
Why?
|
| Biotechnology | 4 | 1999 | 28 | 0.310 |
Why?
|
| In Vitro Techniques | 14 | 2005 | 996 | 0.310 |
Why?
|
| Cattle | 5 | 2023 | 378 | 0.310 |
Why?
|
| Mice, Knockout | 4 | 2021 | 2016 | 0.310 |
Why?
|
| Stem Cell Transplantation | 2 | 2012 | 189 | 0.300 |
Why?
|
| Neurons | 8 | 2019 | 1591 | 0.300 |
Why?
|
| Immunologic Factors | 1 | 2009 | 171 | 0.300 |
Why?
|
| Rabbits | 10 | 2024 | 640 | 0.300 |
Why?
|
| Combinatorial Chemistry Techniques | 2 | 2005 | 7 | 0.300 |
Why?
|
| Escherichia coli | 2 | 2009 | 607 | 0.300 |
Why?
|
| Fracture Fixation | 2 | 2005 | 31 | 0.300 |
Why?
|
| Pyridines | 4 | 2012 | 300 | 0.290 |
Why?
|
| Lymphangiogenesis | 3 | 2021 | 39 | 0.290 |
Why?
|
| Autoantigens | 3 | 2019 | 129 | 0.290 |
Why?
|
| Cellulose | 4 | 1996 | 58 | 0.290 |
Why?
|
| Cats | 2 | 2005 | 305 | 0.290 |
Why?
|
| Microspheres | 4 | 2017 | 108 | 0.290 |
Why?
|
| Hindlimb | 2 | 2021 | 96 | 0.290 |
Why?
|
| Methacrylates | 3 | 2010 | 9 | 0.290 |
Why?
|
| Cell Line | 11 | 2016 | 2495 | 0.290 |
Why?
|
| Gold | 2 | 2009 | 41 | 0.290 |
Why?
|
| Cyclosporine | 1 | 2008 | 238 | 0.290 |
Why?
|
| Adaptive Immunity | 2 | 2020 | 167 | 0.290 |
Why?
|
| Drug Implants | 4 | 2004 | 34 | 0.290 |
Why?
|
| Proteomics | 1 | 2009 | 232 | 0.280 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2019 | 565 | 0.280 |
Why?
|
| HEK293 Cells | 6 | 2021 | 646 | 0.280 |
Why?
|
| Half-Life | 2 | 2020 | 97 | 0.280 |
Why?
|
| Capsules | 6 | 2017 | 37 | 0.280 |
Why?
|
| Acrylic Resins | 4 | 2010 | 23 | 0.280 |
Why?
|
| Male | 35 | 2024 | 42705 | 0.280 |
Why?
|
| Skull | 5 | 2014 | 256 | 0.270 |
Why?
|
| Complement Activation | 4 | 2010 | 81 | 0.270 |
Why?
|
| Glutamate Decarboxylase | 2 | 2016 | 32 | 0.270 |
Why?
|
| Tunica Intima | 3 | 2007 | 60 | 0.270 |
Why?
|
| Platelet-Derived Growth Factor | 4 | 2015 | 66 | 0.270 |
Why?
|
| Molecular Weight | 10 | 2005 | 331 | 0.270 |
Why?
|
| Antibodies, Blocking | 2 | 2024 | 22 | 0.260 |
Why?
|
| Fibroblast Growth Factor 2 | 4 | 2013 | 57 | 0.260 |
Why?
|
| Electrochemistry | 2 | 2003 | 60 | 0.260 |
Why?
|
| Peptide Hydrolases | 2 | 2022 | 101 | 0.260 |
Why?
|
| Skin Transplantation | 2 | 2021 | 184 | 0.250 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2017 | 114 | 0.250 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2005 | 14 | 0.250 |
Why?
|
| Sulfuric Acid Esters | 1 | 2005 | 4 | 0.250 |
Why?
|
| Flow Cytometry | 6 | 2012 | 690 | 0.250 |
Why?
|
| Exosomes | 2 | 2016 | 53 | 0.250 |
Why?
|
| Adhesives | 1 | 2005 | 5 | 0.250 |
Why?
|
| Cytoplasm | 3 | 2017 | 285 | 0.250 |
Why?
|
| Myeloid Cells | 3 | 2015 | 101 | 0.250 |
Why?
|
| Human Growth Hormone | 1 | 2005 | 54 | 0.250 |
Why?
|
| Light | 5 | 2013 | 292 | 0.250 |
Why?
|
| Apoptosis | 6 | 2023 | 1718 | 0.250 |
Why?
|
| Phenotype | 6 | 2024 | 2457 | 0.250 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 3 | 2014 | 69 | 0.250 |
Why?
|
| Antigens, Neoplasm | 3 | 2024 | 334 | 0.240 |
Why?
|
| Phosphorylation | 7 | 2013 | 1130 | 0.240 |
Why?
|
| Adoptive Transfer | 3 | 2021 | 169 | 0.240 |
Why?
|
| Hydrodynamics | 3 | 2014 | 19 | 0.240 |
Why?
|
| Aprotinin | 3 | 2017 | 26 | 0.240 |
Why?
|
| Microscopy | 3 | 2017 | 87 | 0.240 |
Why?
|
| Immunity, Innate | 2 | 2020 | 434 | 0.240 |
Why?
|
| Carotid Arteries | 4 | 2007 | 135 | 0.240 |
Why?
|
| Spectrum Analysis | 2 | 2003 | 119 | 0.240 |
Why?
|
| Integrin alpha3 | 1 | 2024 | 1 | 0.240 |
Why?
|
| Insulin-Secreting Cells | 3 | 2017 | 408 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2016 | 374 | 0.240 |
Why?
|
| Models, Chemical | 2 | 2004 | 179 | 0.240 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 6 | 2010 | 30 | 0.240 |
Why?
|
| Ephrin-B2 | 1 | 2004 | 3 | 0.240 |
Why?
|
| Extraembryonic Membranes | 1 | 2004 | 8 | 0.240 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2019 | 191 | 0.240 |
Why?
|
| Glucose Oxidase | 1 | 2004 | 7 | 0.230 |
Why?
|
| Mice, Inbred DBA | 1 | 2024 | 150 | 0.230 |
Why?
|
| Protein Transport | 2 | 2021 | 423 | 0.230 |
Why?
|
| Thioguanine | 2 | 2015 | 17 | 0.230 |
Why?
|
| Absorbable Implants | 3 | 2005 | 35 | 0.230 |
Why?
|
| Lactoglobulins | 1 | 2023 | 8 | 0.230 |
Why?
|
| HeLa Cells | 6 | 2013 | 515 | 0.230 |
Why?
|
| Cell Division | 9 | 2004 | 692 | 0.230 |
Why?
|
| Lipopolysaccharides | 2 | 2015 | 295 | 0.220 |
Why?
|
| Mannose | 1 | 2023 | 9 | 0.220 |
Why?
|
| Surgical Mesh | 1 | 2024 | 124 | 0.220 |
Why?
|
| Transistors, Electronic | 1 | 2023 | 4 | 0.220 |
Why?
|
| Semiconductors | 1 | 2023 | 11 | 0.220 |
Why?
|
| Blood Vessels | 4 | 2013 | 94 | 0.220 |
Why?
|
| Interleukin-7 | 1 | 2023 | 42 | 0.220 |
Why?
|
| Molecular Structure | 6 | 2010 | 293 | 0.220 |
Why?
|
| Cell Membrane | 7 | 2019 | 677 | 0.220 |
Why?
|
| Poloxalene | 2 | 1995 | 8 | 0.220 |
Why?
|
| Tin Compounds | 1 | 2003 | 2 | 0.220 |
Why?
|
| Blood Platelets | 5 | 1998 | 150 | 0.220 |
Why?
|
| Ovarian Follicle | 2 | 2014 | 72 | 0.220 |
Why?
|
| Optics and Photonics | 1 | 2003 | 27 | 0.220 |
Why?
|
| Proteolysis | 2 | 2014 | 114 | 0.220 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2006 | 241 | 0.220 |
Why?
|
| Technology, Pharmaceutical | 1 | 2003 | 33 | 0.220 |
Why?
|
| Biomimetics | 3 | 2017 | 31 | 0.220 |
Why?
|
| Wearable Electronic Devices | 1 | 2023 | 27 | 0.210 |
Why?
|
| Blood Vessel Prosthesis | 4 | 2007 | 244 | 0.210 |
Why?
|
| Arteries | 1 | 2004 | 179 | 0.210 |
Why?
|
| Peanut Hypersensitivity | 1 | 2022 | 15 | 0.210 |
Why?
|
| Antibodies, Neutralizing | 2 | 2021 | 123 | 0.210 |
Why?
|
| Diffusion | 7 | 2012 | 93 | 0.200 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 228 | 0.200 |
Why?
|
| Serum Albumin, Bovine | 3 | 2009 | 45 | 0.200 |
Why?
|
| Administration, Oral | 1 | 2024 | 667 | 0.200 |
Why?
|
| Umbilical Veins | 6 | 2009 | 46 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 194 | 0.200 |
Why?
|
| Ligands | 4 | 2005 | 447 | 0.200 |
Why?
|
| Urinary Incontinence | 2 | 2017 | 214 | 0.200 |
Why?
|
| Equipment Design | 4 | 2014 | 422 | 0.200 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2001 | 15 | 0.200 |
Why?
|
| Uterus | 4 | 1996 | 222 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 154 | 0.190 |
Why?
|
| Muscle, Smooth | 5 | 2018 | 355 | 0.190 |
Why?
|
| Th17 Cells | 2 | 2020 | 85 | 0.190 |
Why?
|
| Kidney Diseases | 1 | 2024 | 320 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2010 | 1929 | 0.190 |
Why?
|
| Microscopy, Electron, Transmission | 6 | 2016 | 136 | 0.190 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2021 | 276 | 0.190 |
Why?
|
| Nerve Growth Factor | 1 | 2001 | 18 | 0.190 |
Why?
|
| Interleukin-6 | 2 | 2021 | 264 | 0.190 |
Why?
|
| Immunity, Mucosal | 2 | 2012 | 70 | 0.190 |
Why?
|
| Models, Biological | 6 | 2014 | 1766 | 0.190 |
Why?
|
| Bone Substitutes | 4 | 2005 | 9 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor C | 2 | 2021 | 25 | 0.190 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 55 | 0.190 |
Why?
|
| Lymphokines | 1 | 2001 | 75 | 0.190 |
Why?
|
| Neovascularization, Pathologic | 4 | 2022 | 354 | 0.190 |
Why?
|
| Receptors, Fc | 1 | 2021 | 32 | 0.180 |
Why?
|
| Macrophage Activation | 1 | 2021 | 49 | 0.180 |
Why?
|
| Acrylamides | 1 | 2001 | 34 | 0.180 |
Why?
|
| Foot | 1 | 2021 | 53 | 0.180 |
Why?
|
| Tumor Burden | 2 | 2020 | 310 | 0.180 |
Why?
|
| Vesicular Transport Proteins | 1 | 2021 | 63 | 0.180 |
Why?
|
| Rheology | 3 | 2017 | 41 | 0.180 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2019 | 215 | 0.180 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 45 | 0.180 |
Why?
|
| Polymerization | 3 | 2015 | 33 | 0.180 |
Why?
|
| Nerve Growth Factors | 1 | 2000 | 63 | 0.180 |
Why?
|
| Interferon-alpha | 2 | 2011 | 214 | 0.180 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2000 | 5 | 0.180 |
Why?
|
| Gene Expression | 4 | 2012 | 1309 | 0.180 |
Why?
|
| Horseradish Peroxidase | 1 | 2000 | 35 | 0.170 |
Why?
|
| Interleukin-17 | 1 | 2021 | 105 | 0.170 |
Why?
|
| RAW 264.7 Cells | 1 | 2019 | 18 | 0.170 |
Why?
|
| Luminescent Measurements | 3 | 2019 | 64 | 0.170 |
Why?
|
| Immunohistochemistry | 9 | 2019 | 1801 | 0.170 |
Why?
|
| Syndecans | 1 | 2019 | 4 | 0.170 |
Why?
|
| Bone and Bones | 4 | 2012 | 271 | 0.170 |
Why?
|
| Osteoclasts | 1 | 2019 | 36 | 0.170 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2021 | 201 | 0.170 |
Why?
|
| Sialoglycoproteins | 1 | 2019 | 31 | 0.170 |
Why?
|
| Hydrazones | 1 | 2019 | 7 | 0.170 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 311 | 0.170 |
Why?
|
| Colitis | 1 | 2022 | 247 | 0.170 |
Why?
|
| Glass | 2 | 2017 | 15 | 0.170 |
Why?
|
| Carotid Artery Injuries | 2 | 1996 | 22 | 0.170 |
Why?
|
| Injections | 2 | 2017 | 116 | 0.170 |
Why?
|
| Acetylglucosamine | 1 | 2019 | 18 | 0.170 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2019 | 67 | 0.170 |
Why?
|
| Permeability | 5 | 2005 | 138 | 0.160 |
Why?
|
| Chemokines, C | 1 | 2019 | 2 | 0.160 |
Why?
|
| Cell Transplantation | 1 | 1999 | 47 | 0.160 |
Why?
|
| Cadherins | 1 | 2000 | 163 | 0.160 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2016 | 86 | 0.160 |
Why?
|
| Muscle, Skeletal | 4 | 2023 | 471 | 0.160 |
Why?
|
| Spinal Cord Injuries | 1 | 2019 | 64 | 0.160 |
Why?
|
| Protozoan Vaccines | 1 | 2019 | 11 | 0.160 |
Why?
|
| Osteoblasts | 4 | 2014 | 97 | 0.160 |
Why?
|
| Plasmodium falciparum | 1 | 2019 | 47 | 0.160 |
Why?
|
| Oxygen | 1 | 2004 | 746 | 0.160 |
Why?
|
| Hydrolysis | 5 | 2013 | 141 | 0.160 |
Why?
|
| Skin | 5 | 2018 | 589 | 0.160 |
Why?
|
| Magnesium Hydroxide | 1 | 2018 | 1 | 0.160 |
Why?
|
| Interleukin-2 | 1 | 2019 | 241 | 0.150 |
Why?
|
| Urothelium | 3 | 2014 | 62 | 0.150 |
Why?
|
| Cytoskeleton | 4 | 1993 | 195 | 0.150 |
Why?
|
| Remission Induction | 1 | 2020 | 741 | 0.150 |
Why?
|
| Culture Techniques | 4 | 2005 | 91 | 0.150 |
Why?
|
| Polyesters | 3 | 2011 | 42 | 0.150 |
Why?
|
| Poloxamer | 4 | 2013 | 29 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 173 | 0.150 |
Why?
|
| Myocardial Infarction | 2 | 2012 | 380 | 0.150 |
Why?
|
| Lassa virus | 1 | 2017 | 2 | 0.150 |
Why?
|
| Lassa Fever | 1 | 2017 | 4 | 0.150 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 317 | 0.150 |
Why?
|
| Ultrasonics | 2 | 2015 | 39 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2021 | 424 | 0.150 |
Why?
|
| Structure-Activity Relationship | 5 | 2002 | 417 | 0.140 |
Why?
|
| Viral Vaccines | 1 | 2017 | 44 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 280 | 0.140 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2017 | 5 | 0.140 |
Why?
|
| Plasmids | 2 | 2011 | 291 | 0.140 |
Why?
|
| Viral Envelope Proteins | 1 | 2017 | 94 | 0.140 |
Why?
|
| Cilia | 1 | 2017 | 29 | 0.140 |
Why?
|
| Ureter | 2 | 2015 | 95 | 0.140 |
Why?
|
| Thrombin | 3 | 1996 | 61 | 0.140 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2016 | 3 | 0.140 |
Why?
|
| Elastic Modulus | 4 | 2023 | 37 | 0.140 |
Why?
|
| Immunomodulation | 1 | 2017 | 57 | 0.140 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2019 | 198 | 0.140 |
Why?
|
| Chemical Phenomena | 3 | 2005 | 72 | 0.140 |
Why?
|
| Organogenesis | 1 | 2017 | 50 | 0.140 |
Why?
|
| Dexamethasone | 2 | 2010 | 343 | 0.140 |
Why?
|
| Sulfonic Acids | 1 | 2016 | 9 | 0.140 |
Why?
|
| Solvents | 2 | 2008 | 97 | 0.140 |
Why?
|
| Ethylenes | 1 | 2016 | 11 | 0.140 |
Why?
|
| Treatment Outcome | 7 | 2019 | 8292 | 0.140 |
Why?
|
| Signal Transduction | 5 | 2019 | 3404 | 0.140 |
Why?
|
| beta Catenin | 1 | 2018 | 267 | 0.140 |
Why?
|
| Pregnancy Proteins | 2 | 2014 | 37 | 0.130 |
Why?
|
| Microscopy, Fluorescence | 6 | 2001 | 434 | 0.130 |
Why?
|
| Glycoproteins | 1 | 2017 | 235 | 0.130 |
Why?
|
| Ancrod | 1 | 1996 | 2 | 0.130 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2016 | 20 | 0.130 |
Why?
|
| Proinsulin | 1 | 2016 | 124 | 0.130 |
Why?
|
| Titanium | 3 | 2007 | 20 | 0.130 |
Why?
|
| Angioplasty, Balloon | 1 | 1996 | 98 | 0.130 |
Why?
|
| Factor XIIIa | 2 | 2013 | 2 | 0.130 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2016 | 19 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2022 | 594 | 0.130 |
Why?
|
| Streptokinase | 1 | 1995 | 12 | 0.130 |
Why?
|
| Immunization | 2 | 2015 | 163 | 0.130 |
Why?
|
| Hepatitis B virus | 1 | 2016 | 45 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2007 | 603 | 0.130 |
Why?
|
| Leukocytes | 1 | 2017 | 209 | 0.130 |
Why?
|
| Fibrinolysis | 1 | 1996 | 37 | 0.130 |
Why?
|
| Pyroglyphidae | 1 | 2015 | 14 | 0.130 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1995 | 51 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 1066 | 0.130 |
Why?
|
| Amino Acids | 2 | 2010 | 246 | 0.130 |
Why?
|
| Lipid A | 1 | 2015 | 3 | 0.130 |
Why?
|
| Bioreactors | 1 | 2015 | 11 | 0.130 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2015 | 8 | 0.130 |
Why?
|
| Animals, Newborn | 1 | 2017 | 524 | 0.130 |
Why?
|
| Indicators and Reagents | 4 | 2012 | 72 | 0.130 |
Why?
|
| Golgi Apparatus | 1 | 2016 | 116 | 0.130 |
Why?
|
| Hepatitis B | 1 | 2016 | 76 | 0.130 |
Why?
|
| Propylene Glycols | 3 | 2004 | 30 | 0.130 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2007 | 156 | 0.130 |
Why?
|
| Receptor Cross-Talk | 1 | 2015 | 33 | 0.120 |
Why?
|
| Transplants | 2 | 2018 | 42 | 0.120 |
Why?
|
| Swine | 7 | 2014 | 590 | 0.120 |
Why?
|
| Thymoma | 1 | 2015 | 30 | 0.120 |
Why?
|
| Viscosity | 3 | 2017 | 46 | 0.120 |
Why?
|
| Transplantation, Homologous | 2 | 2015 | 995 | 0.120 |
Why?
|
| Heart | 2 | 2023 | 578 | 0.120 |
Why?
|
| Biomechanical Phenomena | 4 | 2013 | 477 | 0.120 |
Why?
|
| Cloning, Molecular | 3 | 2017 | 645 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2005 | 503 | 0.120 |
Why?
|
| Graft Survival | 2 | 2017 | 908 | 0.120 |
Why?
|
| Calcification, Physiologic | 1 | 1994 | 33 | 0.120 |
Why?
|
| Cecal Diseases | 1 | 1994 | 5 | 0.120 |
Why?
|
| Ovarian Diseases | 1 | 1994 | 32 | 0.120 |
Why?
|
| Cell Aggregation | 1 | 2014 | 39 | 0.120 |
Why?
|
| Fibroblast Growth Factors | 1 | 2015 | 81 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2013 | 105 | 0.120 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2015 | 117 | 0.120 |
Why?
|
| PC12 Cells | 3 | 2005 | 115 | 0.120 |
Why?
|
| Blotting, Western | 4 | 2016 | 793 | 0.120 |
Why?
|
| Chemistry, Physical | 2 | 2005 | 29 | 0.120 |
Why?
|
| Organ Culture Techniques | 3 | 2016 | 135 | 0.120 |
Why?
|
| Chimerism | 1 | 2014 | 37 | 0.120 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2013 | 22 | 0.120 |
Why?
|
| Polyethyleneimine | 2 | 2011 | 7 | 0.120 |
Why?
|
| Microscopy, Phase-Contrast | 2 | 2010 | 31 | 0.120 |
Why?
|
| Dextrans | 2 | 2011 | 79 | 0.120 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2014 | 51 | 0.120 |
Why?
|
| Hydrogen | 1 | 1994 | 48 | 0.110 |
Why?
|
| Blood Proteins | 3 | 2003 | 149 | 0.110 |
Why?
|
| Tumor Escape | 1 | 2014 | 51 | 0.110 |
Why?
|
| Immunoprecipitation | 2 | 2004 | 139 | 0.110 |
Why?
|
| Tyrosine | 2 | 2004 | 133 | 0.110 |
Why?
|
| Imides | 1 | 1994 | 26 | 0.110 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1995 | 173 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 276 | 0.110 |
Why?
|
| Ultracentrifugation | 2 | 2010 | 42 | 0.110 |
Why?
|
| Hypersensitivity | 1 | 2015 | 159 | 0.110 |
Why?
|
| Cell Engineering | 1 | 2013 | 5 | 0.110 |
Why?
|
| Nanoconjugates | 1 | 2013 | 2 | 0.110 |
Why?
|
| X-Ray Microtomography | 1 | 2014 | 91 | 0.110 |
Why?
|
| Mice, Inbred Strains | 1 | 2014 | 308 | 0.110 |
Why?
|
| Phototherapy | 1 | 2013 | 35 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2013 | 26 | 0.110 |
Why?
|
| Neutralization Tests | 1 | 2013 | 80 | 0.110 |
Why?
|
| Fluorescent Dyes | 2 | 2013 | 245 | 0.110 |
Why?
|
| Models, Molecular | 3 | 2004 | 1315 | 0.110 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2014 | 61 | 0.110 |
Why?
|
| Carbon Monoxide | 2 | 2010 | 93 | 0.110 |
Why?
|
| Mass Spectrometry | 2 | 2019 | 194 | 0.110 |
Why?
|
| Oxidation-Reduction | 4 | 2012 | 388 | 0.110 |
Why?
|
| Receptors, Laminin | 1 | 1993 | 6 | 0.110 |
Why?
|
| Ibuprofen | 1 | 2013 | 29 | 0.110 |
Why?
|
| Tenascin | 1 | 2013 | 9 | 0.110 |
Why?
|
| Vinculin | 1 | 1993 | 9 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2015 | 198 | 0.110 |
Why?
|
| Macromolecular Substances | 3 | 2003 | 177 | 0.110 |
Why?
|
| Actinin | 1 | 1993 | 19 | 0.110 |
Why?
|
| Sirolimus | 2 | 2011 | 162 | 0.110 |
Why?
|
| Oocytes | 1 | 2014 | 219 | 0.110 |
Why?
|
| Bacterial Adhesion | 2 | 1998 | 84 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2016 | 323 | 0.110 |
Why?
|
| Blood Group Antigens | 1 | 2012 | 17 | 0.110 |
Why?
|
| Microscopy, Electron | 5 | 2004 | 511 | 0.110 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2012 | 21 | 0.100 |
Why?
|
| Infant, Newborn | 2 | 2017 | 2497 | 0.100 |
Why?
|
| Integrin alpha5beta1 | 2 | 2011 | 13 | 0.100 |
Why?
|
| Clonal Anergy | 1 | 2012 | 31 | 0.100 |
Why?
|
| Guided Tissue Regeneration | 1 | 2012 | 7 | 0.100 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 126 | 0.100 |
Why?
|
| Immunoassay | 1 | 2013 | 93 | 0.100 |
Why?
|
| Polyhydroxyethyl Methacrylate | 2 | 1990 | 2 | 0.100 |
Why?
|
| Aorta | 3 | 2010 | 289 | 0.100 |
Why?
|
| Amino Acids, Diamino | 1 | 1992 | 2 | 0.100 |
Why?
|
| Pyrrolidinones | 2 | 2005 | 14 | 0.100 |
Why?
|
| Pluripotent Stem Cells | 1 | 2012 | 34 | 0.100 |
Why?
|
| Amines | 1 | 1992 | 28 | 0.100 |
Why?
|
| Compressive Strength | 2 | 2010 | 24 | 0.100 |
Why?
|
| Growth Substances | 2 | 2004 | 79 | 0.100 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 3022 | 0.100 |
Why?
|
| Cell Membrane Permeability | 1 | 2012 | 120 | 0.100 |
Why?
|
| Myelin Sheath | 2 | 2005 | 85 | 0.100 |
Why?
|
| Microfluidic Analytical Techniques | 2 | 2013 | 46 | 0.100 |
Why?
|
| Injections, Intradermal | 4 | 2013 | 19 | 0.100 |
Why?
|
| Imines | 1 | 2011 | 4 | 0.100 |
Why?
|
| Cholic Acids | 1 | 2011 | 6 | 0.100 |
Why?
|
| Polyethylenes | 1 | 2011 | 7 | 0.100 |
Why?
|
| Immunotoxins | 1 | 2011 | 14 | 0.100 |
Why?
|
| Ferric Compounds | 2 | 2012 | 38 | 0.100 |
Why?
|
| Disaccharides | 1 | 2011 | 23 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 112 | 0.100 |
Why?
|
| Proteoglycans | 1 | 1992 | 123 | 0.100 |
Why?
|
| Biodegradation, Environmental | 3 | 1996 | 18 | 0.100 |
Why?
|
| Acyltransferases | 1 | 2011 | 41 | 0.090 |
Why?
|
| Tuberculosis Vaccines | 1 | 2011 | 18 | 0.090 |
Why?
|
| Caproates | 1 | 2011 | 5 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 244 | 0.090 |
Why?
|
| Chemistry | 2 | 2007 | 54 | 0.090 |
Why?
|
| Lactones | 1 | 2011 | 26 | 0.090 |
Why?
|
| Magnetite Nanoparticles | 1 | 2011 | 27 | 0.090 |
Why?
|
| Ruthenium | 1 | 2010 | 4 | 0.090 |
Why?
|
| Skin Physiological Phenomena | 3 | 2003 | 27 | 0.090 |
Why?
|
| Calibration | 4 | 2005 | 103 | 0.090 |
Why?
|
| Coagulants | 2 | 2001 | 7 | 0.090 |
Why?
|
| Polyglactin 910 | 1 | 1990 | 5 | 0.090 |
Why?
|
| Receptors, Immunologic | 1 | 1991 | 136 | 0.090 |
Why?
|
| Temperature | 3 | 2004 | 409 | 0.090 |
Why?
|
| CpG Islands | 1 | 2011 | 158 | 0.090 |
Why?
|
| Nanopores | 1 | 2010 | 8 | 0.090 |
Why?
|
| Models, Animal | 3 | 2019 | 277 | 0.090 |
Why?
|
| Lactic Acid | 1 | 2011 | 93 | 0.090 |
Why?
|
| Antigens, Bacterial | 1 | 2011 | 136 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2014 | 283 | 0.090 |
Why?
|
| Emulsions | 1 | 2010 | 19 | 0.090 |
Why?
|
| Cytological Techniques | 1 | 2010 | 30 | 0.090 |
Why?
|
| Coculture Techniques | 3 | 2017 | 176 | 0.090 |
Why?
|
| Chromatography, Affinity | 2 | 2000 | 81 | 0.090 |
Why?
|
| Adenoviridae | 1 | 2011 | 349 | 0.090 |
Why?
|
| Polyethylene | 1 | 2010 | 7 | 0.090 |
Why?
|
| Cartilage | 2 | 2008 | 117 | 0.090 |
Why?
|
| Genetic Enhancement | 1 | 2009 | 2 | 0.090 |
Why?
|
| Tacrolimus | 1 | 2011 | 369 | 0.090 |
Why?
|
| Abdomen | 3 | 2007 | 124 | 0.090 |
Why?
|
| Nitric Oxide Donors | 1 | 2009 | 12 | 0.090 |
Why?
|
| Adipose Tissue | 2 | 2014 | 262 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2014 | 1102 | 0.080 |
Why?
|
| Organometallic Compounds | 1 | 2010 | 138 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2011 | 122 | 0.080 |
Why?
|
| Glucose | 4 | 2017 | 629 | 0.080 |
Why?
|
| alpha-2-Antiplasmin | 3 | 2011 | 6 | 0.080 |
Why?
|
| Electrodes | 2 | 2003 | 88 | 0.080 |
Why?
|
| Eosine Yellowish-(YS) | 2 | 2000 | 11 | 0.080 |
Why?
|
| Wheat Germ Agglutinins | 2 | 2000 | 16 | 0.080 |
Why?
|
| Ethanolamines | 2 | 2000 | 24 | 0.080 |
Why?
|
| Spectrometry, Mass, Secondary Ion | 1 | 2009 | 2 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2011 | 275 | 0.080 |
Why?
|
| DNA, Viral | 1 | 2010 | 263 | 0.080 |
Why?
|
| Sulfates | 1 | 2009 | 57 | 0.080 |
Why?
|
| Streptavidin | 1 | 2009 | 14 | 0.080 |
Why?
|
| Peptide Library | 2 | 2008 | 84 | 0.080 |
Why?
|
| Collagen Type I | 1 | 2009 | 72 | 0.080 |
Why?
|
| Solutions | 2 | 2009 | 86 | 0.080 |
Why?
|
| Autoantibodies | 2 | 2022 | 270 | 0.080 |
Why?
|
| Systems Integration | 1 | 2008 | 36 | 0.080 |
Why?
|
| Biological Science Disciplines | 1 | 2008 | 12 | 0.080 |
Why?
|
| Spectrophotometry | 1 | 2008 | 108 | 0.080 |
Why?
|
| Pharmaceutical Vehicles | 2 | 2006 | 10 | 0.080 |
Why?
|
| Nitric Oxide | 1 | 2009 | 280 | 0.080 |
Why?
|
| Cell Fractionation | 1 | 2008 | 71 | 0.070 |
Why?
|
| Photosensitizing Agents | 1 | 2008 | 51 | 0.070 |
Why?
|
| Magnetics | 1 | 2008 | 41 | 0.070 |
Why?
|
| Extracellular Fluid | 1 | 2008 | 25 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2770 | 0.070 |
Why?
|
| Carpus, Animal | 2 | 2005 | 2 | 0.070 |
Why?
|
| Parathyroid Hormone | 1 | 2009 | 220 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 198 | 0.070 |
Why?
|
| Piperazines | 1 | 2009 | 283 | 0.070 |
Why?
|
| Neurotrophin 3 | 2 | 2013 | 3 | 0.070 |
Why?
|
| Joint Diseases | 1 | 2008 | 49 | 0.070 |
Why?
|
| Myocardium | 1 | 2010 | 573 | 0.070 |
Why?
|
| Lymphatic System | 1 | 2007 | 55 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 889 | 0.070 |
Why?
|
| Osseointegration | 2 | 2004 | 11 | 0.070 |
Why?
|
| Receptors, Fibronectin | 2 | 2001 | 5 | 0.070 |
Why?
|
| Enzymes | 1 | 2007 | 47 | 0.070 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 27 | 0.070 |
Why?
|
| Cryoelectron Microscopy | 1 | 2008 | 102 | 0.070 |
Why?
|
| Platelet Adhesiveness | 3 | 1991 | 8 | 0.070 |
Why?
|
| Neuropilin-1 | 2 | 2019 | 14 | 0.070 |
Why?
|
| Static Electricity | 1 | 2007 | 90 | 0.070 |
Why?
|
| Wounds and Injuries | 2 | 2003 | 265 | 0.070 |
Why?
|
| Photons | 1 | 2007 | 47 | 0.070 |
Why?
|
| Coronary Restenosis | 1 | 2006 | 11 | 0.070 |
Why?
|
| Cell Polarity | 1 | 2007 | 116 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2016 | 269 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 262 | 0.070 |
Why?
|
| Substrate Specificity | 2 | 2002 | 352 | 0.070 |
Why?
|
| Transcription Factor RelA | 1 | 2006 | 50 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2012 | 86 | 0.070 |
Why?
|
| RNA Interference | 1 | 2007 | 376 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 2 | 1996 | 101 | 0.060 |
Why?
|
| Zinc Acetate | 1 | 2005 | 1 | 0.060 |
Why?
|
| gamma-Globulins | 1 | 2005 | 16 | 0.060 |
Why?
|
| Excipients | 2 | 2012 | 54 | 0.060 |
Why?
|
| Vaccines, Synthetic | 2 | 2019 | 56 | 0.060 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2017 | 135 | 0.060 |
Why?
|
| Femoral Artery | 1 | 2005 | 84 | 0.060 |
Why?
|
| Morphogenesis | 2 | 2004 | 207 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2007 | 521 | 0.060 |
Why?
|
| Angiopoietin-1 | 1 | 2005 | 7 | 0.060 |
Why?
|
| Tensile Strength | 1 | 2005 | 82 | 0.060 |
Why?
|
| Biotransformation | 1 | 2005 | 49 | 0.060 |
Why?
|
| Polyvinyls | 1 | 2005 | 17 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 901 | 0.060 |
Why?
|
| Chorioallantoic Membrane | 1 | 2004 | 4 | 0.060 |
Why?
|
| Lysine | 1 | 2005 | 152 | 0.060 |
Why?
|
| Scattering, Radiation | 1 | 2005 | 117 | 0.060 |
Why?
|
| Models, Theoretical | 2 | 2015 | 493 | 0.060 |
Why?
|
| Drug Compounding | 2 | 1998 | 85 | 0.060 |
Why?
|
| Allografts | 2 | 2017 | 184 | 0.060 |
Why?
|
| Gene Targeting | 1 | 2005 | 74 | 0.060 |
Why?
|
| Receptors, Cell Surface | 2 | 2000 | 288 | 0.060 |
Why?
|
| Tissue Distribution | 2 | 2017 | 293 | 0.060 |
Why?
|
| Genetic Engineering | 2 | 2017 | 115 | 0.060 |
Why?
|
| Chickens | 1 | 2004 | 212 | 0.060 |
Why?
|
| Hydroxylation | 1 | 2004 | 17 | 0.060 |
Why?
|
| Fractures, Ununited | 1 | 2004 | 9 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2004 | 272 | 0.060 |
Why?
|
| Sodium Hydroxide | 1 | 2004 | 5 | 0.060 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2007 | 85 | 0.060 |
Why?
|
| Transgenes | 1 | 2004 | 185 | 0.060 |
Why?
|
| Aged | 1 | 2021 | 19272 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2004 | 143 | 0.060 |
Why?
|
| Ethylene Glycols | 1 | 2003 | 10 | 0.060 |
Why?
|
| Dystroglycans | 1 | 2003 | 15 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 70 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 77 | 0.060 |
Why?
|
| Rats, Wistar | 2 | 2005 | 303 | 0.060 |
Why?
|
| Plasma | 1 | 2003 | 51 | 0.060 |
Why?
|
| Chondrocytes | 1 | 2004 | 65 | 0.060 |
Why?
|
| Peripheral Nerves | 1 | 2003 | 37 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 44 | 0.060 |
Why?
|
| Alkenes | 1 | 2003 | 14 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2012 | 899 | 0.060 |
Why?
|
| Electronics | 1 | 2023 | 17 | 0.060 |
Why?
|
| Glycosaminoglycans | 1 | 2003 | 47 | 0.060 |
Why?
|
| Folic Acid | 2 | 2015 | 63 | 0.050 |
Why?
|
| Cricetulus | 2 | 2019 | 127 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2013 | 696 | 0.050 |
Why?
|
| CHO Cells | 2 | 2019 | 188 | 0.050 |
Why?
|
| DNA Adducts | 1 | 2003 | 21 | 0.050 |
Why?
|
| Ultraviolet Rays | 2 | 1995 | 195 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2019 | 449 | 0.050 |
Why?
|
| Stents | 1 | 2006 | 412 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2005 | 293 | 0.050 |
Why?
|
| Transducers | 1 | 2003 | 42 | 0.050 |
Why?
|
| Electrophysiological Phenomena | 1 | 2023 | 51 | 0.050 |
Why?
|
| Blood Cells | 1 | 2003 | 33 | 0.050 |
Why?
|
| Capillary Permeability | 2 | 2019 | 132 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 283 | 0.050 |
Why?
|
| Endosomes | 1 | 2003 | 79 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2022 | 31 | 0.050 |
Why?
|
| Cricetinae | 2 | 2019 | 558 | 0.050 |
Why?
|
| Antithrombin III | 1 | 2002 | 9 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2003 | 118 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 44 | 0.050 |
Why?
|
| Liposomes | 2 | 2016 | 93 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2022 | 93 | 0.050 |
Why?
|
| Insulin | 3 | 2017 | 1148 | 0.050 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2022 | 3 | 0.050 |
Why?
|
| Elasticity | 3 | 2010 | 97 | 0.050 |
Why?
|
| Surface Plasmon Resonance | 2 | 2013 | 47 | 0.050 |
Why?
|
| Endocytosis | 1 | 2003 | 180 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 274 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2004 | 474 | 0.050 |
Why?
|
| Boronic Acids | 1 | 2002 | 54 | 0.050 |
Why?
|
| Thermodynamics | 2 | 2015 | 314 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2004 | 726 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2005 | 4329 | 0.050 |
Why?
|
| Chromatography, Gel | 2 | 2007 | 103 | 0.050 |
Why?
|
| Cell Shape | 2 | 2015 | 51 | 0.050 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2001 | 48 | 0.050 |
Why?
|
| Administration, Intranasal | 2 | 2012 | 139 | 0.050 |
Why?
|
| Complement System Proteins | 2 | 2011 | 82 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 56 | 0.050 |
Why?
|
| Protease Inhibitors | 2 | 2005 | 72 | 0.050 |
Why?
|
| Radiography | 3 | 2012 | 808 | 0.050 |
Why?
|
| Mitogens | 1 | 2001 | 62 | 0.050 |
Why?
|
| Giant Cells | 1 | 2001 | 19 | 0.050 |
Why?
|
| Base Sequence | 1 | 2005 | 2329 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2022 | 906 | 0.050 |
Why?
|
| Luciferases | 2 | 2014 | 128 | 0.050 |
Why?
|
| Hot Temperature | 2 | 2000 | 207 | 0.050 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2000 | 27 | 0.050 |
Why?
|
| Nylons | 2 | 2013 | 7 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 415 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2003 | 872 | 0.040 |
Why?
|
| Spinal Nerve Roots | 1 | 2000 | 17 | 0.040 |
Why?
|
| Thymosin | 2 | 2010 | 6 | 0.040 |
Why?
|
| Polyurethanes | 2 | 1992 | 13 | 0.040 |
Why?
|
| Mannans | 1 | 2000 | 5 | 0.040 |
Why?
|
| Agglutination Tests | 1 | 2000 | 11 | 0.040 |
Why?
|
| Erythrocyte Aggregation | 1 | 2000 | 4 | 0.040 |
Why?
|
| Calcium | 2 | 2017 | 1179 | 0.040 |
Why?
|
| Nerve Tissue | 1 | 2019 | 8 | 0.040 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2000 | 36 | 0.040 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2019 | 21 | 0.040 |
Why?
|
| Porosity | 2 | 2013 | 61 | 0.040 |
Why?
|
| Fluorescence | 2 | 2012 | 103 | 0.040 |
Why?
|
| Receptors, Growth Factor | 1 | 2019 | 52 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2012 | 837 | 0.040 |
Why?
|
| Drug Stability | 2 | 2003 | 52 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2000 | 98 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 2000 | 40 | 0.040 |
Why?
|
| Tissue Transplantation | 1 | 1999 | 12 | 0.040 |
Why?
|
| Complement C3 | 2 | 2010 | 58 | 0.040 |
Why?
|
| Analgesia | 1 | 2000 | 58 | 0.040 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1999 | 44 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 495 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 2019 | 144 | 0.040 |
Why?
|
| Morphine | 1 | 2000 | 130 | 0.040 |
Why?
|
| Urinary Tract | 1 | 2019 | 34 | 0.040 |
Why?
|
| Anions | 1 | 1998 | 31 | 0.040 |
Why?
|
| Microelectrodes | 2 | 2010 | 83 | 0.040 |
Why?
|
| Myoglobin | 1 | 1998 | 29 | 0.040 |
Why?
|
| Alkylation | 2 | 1996 | 31 | 0.040 |
Why?
|
| U937 Cells | 1 | 2018 | 32 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 2018 | 0.040 |
Why?
|
| Drug-Eluting Stents | 1 | 2018 | 17 | 0.040 |
Why?
|
| Vitamin B 12 | 1 | 1998 | 24 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 1998 | 72 | 0.040 |
Why?
|
| Ethidium | 1 | 1998 | 13 | 0.040 |
Why?
|
| Hemagglutination Tests | 1 | 1998 | 11 | 0.040 |
Why?
|
| Fluoresceins | 1 | 1998 | 43 | 0.040 |
Why?
|
| Dietary Fiber | 1 | 2018 | 44 | 0.040 |
Why?
|
| Dimethylformamide | 1 | 1998 | 2 | 0.040 |
Why?
|
| Pelvis | 1 | 1998 | 96 | 0.040 |
Why?
|
| Electric Impedance | 2 | 2010 | 111 | 0.040 |
Why?
|
| Injections, Intramuscular | 2 | 2013 | 64 | 0.040 |
Why?
|
| Axons | 1 | 1999 | 181 | 0.040 |
Why?
|
| Electron Probe Microanalysis | 1 | 1998 | 8 | 0.040 |
Why?
|
| Benzophenones | 1 | 1998 | 12 | 0.040 |
Why?
|
| Random Allocation | 2 | 2000 | 327 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 1999 | 368 | 0.040 |
Why?
|
| Lasers | 1 | 1998 | 107 | 0.040 |
Why?
|
| Azo Compounds | 2 | 2009 | 14 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1998 | 1255 | 0.040 |
Why?
|
| A549 Cells | 1 | 2017 | 42 | 0.040 |
Why?
|
| Transplantation Immunology | 1 | 1997 | 81 | 0.040 |
Why?
|
| Electrodes, Implanted | 2 | 2010 | 185 | 0.040 |
Why?
|
| Pancreas, Artificial | 1 | 1997 | 28 | 0.040 |
Why?
|
| Silver | 1 | 2017 | 16 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 140 | 0.040 |
Why?
|
| Nanocomposites | 1 | 2017 | 14 | 0.040 |
Why?
|
| Pain | 1 | 2000 | 400 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2017 | 93 | 0.040 |
Why?
|
| HLA-DR4 Antigen | 1 | 2016 | 2 | 0.040 |
Why?
|
| Calreticulin | 1 | 2016 | 13 | 0.030 |
Why?
|
| Protein Conformation | 1 | 1999 | 895 | 0.030 |
Why?
|
| Germinal Center | 1 | 2017 | 55 | 0.030 |
Why?
|
| Staphylococcus epidermidis | 2 | 1998 | 15 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2000 | 432 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2017 | 82 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2001 | 689 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 885 | 0.030 |
Why?
|
| Microtubules | 1 | 2017 | 123 | 0.030 |
Why?
|
| Implants, Experimental | 1 | 2016 | 16 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 1863 | 0.030 |
Why?
|
| Sodium | 1 | 1998 | 333 | 0.030 |
Why?
|
| Rats, Nude | 1 | 2016 | 25 | 0.030 |
Why?
|
| Lipoylation | 1 | 2016 | 30 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1998 | 469 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2016 | 115 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2016 | 85 | 0.030 |
Why?
|
| Pregnancy | 2 | 2013 | 3046 | 0.030 |
Why?
|
| Mechanical Phenomena | 1 | 2015 | 15 | 0.030 |
Why?
|
| Factor XIII | 2 | 2005 | 5 | 0.030 |
Why?
|
| 3T3 Cells | 2 | 2005 | 97 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2000 | 451 | 0.030 |
Why?
|
| Drug Liberation | 1 | 2015 | 16 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2015 | 192 | 0.030 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2017 | 120 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2023 | 1545 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1995 | 146 | 0.030 |
Why?
|
| Receptor, TIE-2 | 2 | 2005 | 18 | 0.030 |
Why?
|
| Postoperative Care | 1 | 1996 | 232 | 0.030 |
Why?
|
| Blood Physiological Phenomena | 1 | 1994 | 9 | 0.030 |
Why?
|
| Pancreas | 1 | 2016 | 253 | 0.030 |
Why?
|
| Haplotypes | 1 | 2016 | 637 | 0.030 |
Why?
|
| Liver | 1 | 2019 | 1211 | 0.030 |
Why?
|
| Microscopy, Confocal | 2 | 2009 | 280 | 0.030 |
Why?
|
| Heparitin Sulfate | 1 | 2014 | 27 | 0.030 |
Why?
|
| Fatty Acids | 1 | 1995 | 134 | 0.030 |
Why?
|
| Forecasting | 1 | 1995 | 304 | 0.030 |
Why?
|
| Keratin-16 | 1 | 2013 | 1 | 0.030 |
Why?
|
| Chemokine CXCL11 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Photolysis | 1 | 2013 | 13 | 0.030 |
Why?
|
| Microtechnology | 1 | 2013 | 3 | 0.030 |
Why?
|
| Enzymes, Immobilized | 1 | 2013 | 11 | 0.030 |
Why?
|
| Chemokine CXCL9 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2013 | 12 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 1995 | 149 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2013 | 22 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 1996 | 227 | 0.030 |
Why?
|
| Actins | 1 | 2017 | 462 | 0.030 |
Why?
|
| Clone Cells | 1 | 2014 | 214 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 1995 | 277 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1994 | 270 | 0.030 |
Why?
|
| Vaccines, Subunit | 1 | 2013 | 55 | 0.030 |
Why?
|
| Fertilization | 1 | 2013 | 41 | 0.030 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2013 | 14 | 0.030 |
Why?
|
| Preoperative Care | 1 | 1996 | 395 | 0.030 |
Why?
|
| Sf9 Cells | 1 | 2013 | 7 | 0.030 |
Why?
|
| Fetal Development | 1 | 2013 | 31 | 0.030 |
Why?
|
| Hippocampus | 1 | 2017 | 449 | 0.030 |
Why?
|
| Immune Sera | 1 | 1993 | 52 | 0.030 |
Why?
|
| Protons | 1 | 1994 | 101 | 0.030 |
Why?
|
| Biocatalysis | 1 | 2013 | 50 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 2013 | 14 | 0.030 |
Why?
|
| Flow Injection Analysis | 1 | 2013 | 3 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2013 | 48 | 0.030 |
Why?
|
| Ovary | 1 | 1994 | 262 | 0.030 |
Why?
|
| Abortion, Spontaneous | 1 | 2013 | 66 | 0.030 |
Why?
|
| Embryonic Development | 1 | 2013 | 79 | 0.030 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2012 | 4 | 0.030 |
Why?
|
| Karyotyping | 1 | 2013 | 252 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 91 | 0.030 |
Why?
|
| Cornea | 1 | 1993 | 70 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 89 | 0.030 |
Why?
|
| Keratinocytes | 1 | 2013 | 146 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 231 | 0.030 |
Why?
|
| Connective Tissue | 1 | 2012 | 23 | 0.030 |
Why?
|
| Aminoquinolines | 1 | 2012 | 17 | 0.030 |
Why?
|
| Diamines | 1 | 1992 | 11 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 397 | 0.030 |
Why?
|
| Cycloheximide | 1 | 1992 | 56 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2012 | 58 | 0.030 |
Why?
|
| Toll-Like Receptors | 1 | 2013 | 93 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 86 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 201 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2013 | 278 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 95 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 1992 | 21 | 0.020 |
Why?
|
| Foreign-Body Reaction | 1 | 1992 | 12 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 1992 | 73 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 476 | 0.020 |
Why?
|
| Penis | 1 | 2012 | 61 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2011 | 35 | 0.020 |
Why?
|
| Receptors, Vitronectin | 1 | 1991 | 5 | 0.020 |
Why?
|
| Toxicity Tests | 1 | 2011 | 13 | 0.020 |
Why?
|
| Peritoneum | 1 | 1992 | 57 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 44 | 0.020 |
Why?
|
| Administration, Intravesical | 1 | 2011 | 34 | 0.020 |
Why?
|
| Pregnadienediols | 1 | 2011 | 13 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 303 | 0.020 |
Why?
|
| Mometasone Furoate | 1 | 2011 | 18 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2013 | 258 | 0.020 |
Why?
|
| Serum Albumin, Radio-Iodinated | 1 | 1991 | 6 | 0.020 |
Why?
|
| Ethylenediamines | 1 | 1991 | 14 | 0.020 |
Why?
|
| Placenta | 1 | 2013 | 181 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2011 | 109 | 0.020 |
Why?
|
| Algorithms | 1 | 2000 | 1913 | 0.020 |
Why?
|
| Video Recording | 1 | 1992 | 203 | 0.020 |
Why?
|
| Polysaccharides | 1 | 2012 | 91 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 1048 | 0.020 |
Why?
|
| Complement Pathway, Alternative | 1 | 2010 | 13 | 0.020 |
Why?
|
| Factor X | 1 | 1990 | 3 | 0.020 |
Why?
|
| Prothrombin | 1 | 1990 | 17 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 1990 | 25 | 0.020 |
Why?
|
| Pinocytosis | 1 | 2010 | 6 | 0.020 |
Why?
|
| Clathrin-Coated Vesicles | 1 | 2010 | 7 | 0.020 |
Why?
|
| Triazines | 1 | 1991 | 54 | 0.020 |
Why?
|
| Culture Media | 1 | 1991 | 147 | 0.020 |
Why?
|
| Viruses | 1 | 2011 | 78 | 0.020 |
Why?
|
| Antithrombins | 1 | 1990 | 16 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 1990 | 44 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2010 | 15 | 0.020 |
Why?
|
| Platelet Count | 1 | 1990 | 93 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 309 | 0.020 |
Why?
|
| Research | 1 | 2012 | 251 | 0.020 |
Why?
|
| Albumins | 1 | 1991 | 129 | 0.020 |
Why?
|
| Surface Tension | 1 | 2010 | 8 | 0.020 |
Why?
|
| Bacteriophage lambda | 1 | 2010 | 23 | 0.020 |
Why?
|
| Plastics | 1 | 2010 | 7 | 0.020 |
Why?
|
| Photoelectron Spectroscopy | 1 | 2010 | 2 | 0.020 |
Why?
|
| Polymethacrylic Acids | 1 | 2010 | 3 | 0.020 |
Why?
|
| Biotin | 1 | 2010 | 45 | 0.020 |
Why?
|
| Halogenation | 1 | 2010 | 6 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1992 | 184 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1992 | 203 | 0.020 |
Why?
|
| Nasal Mucosa | 1 | 2010 | 191 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2010 | 50 | 0.020 |
Why?
|
| Rectum | 1 | 2010 | 148 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 1992 | 204 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1452 | 0.020 |
Why?
|
| Vagina | 1 | 2010 | 177 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2009 | 96 | 0.020 |
Why?
|
| Receptors, Parathyroid Hormone | 1 | 2009 | 1 | 0.020 |
Why?
|
| Thromboxane A2 | 1 | 1989 | 10 | 0.020 |
Why?
|
| Platelet Activation | 1 | 1989 | 14 | 0.020 |
Why?
|
| United States | 1 | 2022 | 7114 | 0.020 |
Why?
|
| Videotape Recording | 1 | 1989 | 48 | 0.020 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2011 | 197 | 0.020 |
Why?
|
| Biological Assay | 1 | 2009 | 79 | 0.020 |
Why?
|
| Embolism | 1 | 1989 | 33 | 0.020 |
Why?
|
| Sheep | 1 | 2009 | 251 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 1992 | 278 | 0.020 |
Why?
|
| Protein Stability | 1 | 2008 | 101 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 785 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2008 | 14 | 0.020 |
Why?
|
| Mitochondrial Membranes | 1 | 2008 | 15 | 0.020 |
Why?
|
| Electrophoresis | 1 | 2007 | 55 | 0.020 |
Why?
|
| Integrin beta Chains | 1 | 2007 | 3 | 0.020 |
Why?
|
| Injections, Intra-Articular | 1 | 2008 | 31 | 0.020 |
Why?
|
| Oscillometry | 1 | 2007 | 25 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2010 | 314 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 2360 | 0.020 |
Why?
|
| Metalloendopeptidases | 1 | 2007 | 44 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2007 | 96 | 0.020 |
Why?
|
| Serotonin | 1 | 1989 | 221 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2007 | 39 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 43 | 0.020 |
Why?
|
| Resins, Synthetic | 1 | 2007 | 1 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2007 | 51 | 0.020 |
Why?
|
| Luminescence | 1 | 2007 | 21 | 0.020 |
Why?
|
| Finite Element Analysis | 1 | 2007 | 78 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2007 | 274 | 0.020 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2006 | 5 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2007 | 129 | 0.020 |
Why?
|
| Thromboxane B2 | 1 | 1986 | 11 | 0.020 |
Why?
|
| Capillaries | 1 | 2007 | 90 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2007 | 92 | 0.020 |
Why?
|
| Platinum | 1 | 2007 | 64 | 0.020 |
Why?
|
| Coronary Thrombosis | 1 | 2006 | 14 | 0.020 |
Why?
|
| Biological Transport | 1 | 2007 | 401 | 0.020 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2007 | 99 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 1986 | 56 | 0.020 |
Why?
|
| Lysosomes | 1 | 2007 | 113 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2006 | 81 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2006 | 66 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2006 | 152 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2007 | 340 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2006 | 86 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2006 | 96 | 0.020 |
Why?
|
| GAP-43 Protein | 1 | 2005 | 2 | 0.020 |
Why?
|
| Adult | 2 | 2017 | 26836 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1986 | 202 | 0.020 |
Why?
|
| Sepharose | 1 | 2005 | 14 | 0.020 |
Why?
|
| Myelin Basic Protein | 1 | 2005 | 50 | 0.020 |
Why?
|
| Synchrotrons | 1 | 2005 | 29 | 0.020 |
Why?
|
| Biotinylation | 1 | 2005 | 42 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2005 | 59 | 0.020 |
Why?
|
| Cells, Immobilized | 1 | 2004 | 2 | 0.020 |
Why?
|
| Baculoviridae | 1 | 2005 | 34 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2005 | 42 | 0.020 |
Why?
|
| Lentivirus | 1 | 2005 | 43 | 0.020 |
Why?
|
| COS Cells | 1 | 2005 | 167 | 0.010 |
Why?
|
| Mathematics | 1 | 2005 | 191 | 0.010 |
Why?
|
| Insecta | 1 | 2005 | 49 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 6418 | 0.010 |
Why?
|
| Motor Cortex | 1 | 2007 | 200 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2007 | 227 | 0.010 |
Why?
|
| Allantois | 1 | 2004 | 3 | 0.010 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2004 | 4 | 0.010 |
Why?
|
| Metacarpus | 1 | 2004 | 5 | 0.010 |
Why?
|
| Chorion | 1 | 2004 | 14 | 0.010 |
Why?
|
| Parietal Bone | 1 | 2004 | 20 | 0.010 |
Why?
|
| Osteocalcin | 1 | 2004 | 26 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 198 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 9347 | 0.010 |
Why?
|
| Femoral Fractures | 1 | 2004 | 27 | 0.010 |
Why?
|
| Tibial Fractures | 1 | 2004 | 36 | 0.010 |
Why?
|
| Mitochondria | 1 | 2008 | 556 | 0.010 |
Why?
|
| Arthrodesis | 1 | 2004 | 32 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2004 | 132 | 0.010 |
Why?
|
| Myosin Heavy Chains | 1 | 2004 | 92 | 0.010 |
Why?
|
| Radius Fractures | 1 | 2004 | 33 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2004 | 158 | 0.010 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2003 | 10 | 0.010 |
Why?
|
| Skull Fractures | 1 | 2003 | 25 | 0.010 |
Why?
|
| Indoles | 1 | 2005 | 301 | 0.010 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2003 | 25 | 0.010 |
Why?
|
| Shear Strength | 1 | 2003 | 18 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2003 | 253 | 0.010 |
Why?
|
| Administration, Rectal | 1 | 2000 | 12 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2000 | 42 | 0.010 |
Why?
|
| Brain | 1 | 2010 | 2306 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 3481 | 0.010 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2000 | 79 | 0.010 |
Why?
|
| Oligochaeta | 1 | 1999 | 2 | 0.010 |
Why?
|
| Sciatic Nerve | 1 | 1999 | 34 | 0.010 |
Why?
|
| Peripheral Nervous System | 1 | 1999 | 21 | 0.010 |
Why?
|
| Pressure | 1 | 2000 | 167 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2000 | 338 | 0.010 |
Why?
|
| Sucrose | 1 | 1999 | 65 | 0.010 |
Why?
|
| Central Nervous System | 1 | 1999 | 153 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 26173 | 0.010 |
Why?
|
| Species Specificity | 1 | 1999 | 685 | 0.010 |
Why?
|
| Heart Rate | 1 | 2000 | 498 | 0.010 |
Why?
|
| Complement C4a | 1 | 1996 | 3 | 0.010 |
Why?
|
| Complement C3a | 1 | 1996 | 11 | 0.010 |
Why?
|
| Complement C5a | 1 | 1996 | 24 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 2677 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 2507 | 0.010 |
Why?
|